What similarly acting projects are still unpartnered?

Efficacy with Torl’s ADC looks in line, while toxicity with BNT211 still looms large.

If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise.

Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.

The small cap biotech Instil Bio tries to follow in Summit’s slipstream.

Bicara and DualityBio will soon test market appetite for new oncology issues.

BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.

But the company hasn’t given details, and used a historical control rather than the study’s own control arm.

The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.